Kingsview Wealth Management LLC Raises Stock Position in Zoetis Inc. (NYSE:ZTS)

Kingsview Wealth Management LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 1.0% in the 4th quarter, HoldingsChannel reports. The firm owned 9,986 shares of the company’s stock after buying an additional 97 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Zoetis were worth $1,627,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Pensionfund Sabic boosted its position in Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after acquiring an additional 4,000 shares in the last quarter. PFW Advisors LLC purchased a new position in shares of Zoetis in the 4th quarter valued at approximately $1,764,000. JPMorgan Chase & Co. boosted its position in shares of Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after purchasing an additional 279,092 shares in the last quarter. Simplify Asset Management Inc. purchased a new stake in Zoetis in the third quarter worth $11,684,000. Finally, Nordea Investment Management AB raised its holdings in Zoetis by 38.3% in the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after purchasing an additional 572,511 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $171.71 on Tuesday. The company has a market cap of $77.47 billion, a price-to-earnings ratio of 32.28, a P/E/G ratio of 2.77 and a beta of 0.90. The business’s fifty day simple moving average is $169.26 and its two-hundred day simple moving average is $179.21. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.16%. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ZTS shares. Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Morgan Stanley dropped their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Piper Sandler dropped their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $214.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.